Dorzagliatin (BioDeep_00000802741)
代谢物信息卡片
化学式: C22H27ClN4O5 (462.16698820000005)
中文名称: 多扎格列亚汀
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C)CC(C(=O)NC1=NN(C=C1)CC(CO)O)N2CC(=CC2=O)OC3=CC=CC=C3Cl
InChI: InChI=1S/C22H27ClN4O5/c1-14(2)9-18(22(31)24-20-7-8-26(25-20)11-15(29)13-28)27-12-16(10-21(27)30)32-19-6-4-3-5-17(19)23/h3-8,10,14-15,18,28-29H,9,11-13H2,1-2H3,(H,24,25,31)/t15-,18+/m1/s1
描述信息
A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins
C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- KEGGdrug: D83693
- KEGGdrug: D11342
- PubChem: 57920094
- DrugBank: DB15123
- ChEMBL: CHEMBL4297508
- CAS: 1191995-00-2
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Upinder Kaur, Bhairav Kumar Pathak, Tharik Jalal Meerashahib, Dondapati Venkata Vamshi Krishna, Sankha Shubhra Chakrabarti. Should Glucokinase be Given a Chance in Diabetes Therapeutics? A Clinical-Pharmacological Review of Dorzagliatin and Lessons Learned So Far.
Clinical drug investigation.
2024 Apr; 44(4):223-250. doi:
10.1007/s40261-024-01351-5. [PMID: 38460077] - Yuqian Wu, Kai Wang, Jingyang Su, Xin Liu. Efficacy and safety of dorzagliatin, a novel glucokinase activators, in the treatment of T2DM: A meta-analysis of randomized controlled trials.
Medicine.
2024 Feb; 103(8):e36916. doi:
10.1097/md.0000000000036916. [PMID: 38394489] - Wenying Yang, Dalong Zhu, Shenglian Gan, Xiaolin Dong, Junping Su, Wenhui Li, Hongwei Jiang, Wenjuan Zhao, Minxiu Yao, Weihong Song, Yibing Lu, Xiuzhen Zhang, Huifang Li, Guixia Wang, Wei Qiu, Guoyue Yuan, Jianhua Ma, Wei Li, Ziling Li, Xiaoyue Wang, Jiao'e Zeng, Zhou Yang, Jingdong Liu, Yongqian Liang, Song Lu, Huili Zhang, Hui Liu, Ping Liu, Kuanlu Fan, Xiaozhen Jiang, Yufeng Li, Qing Su, Tao Ning, Huiwen Tan, Zhenmei An, Zhaoshun Jiang, Lijun Liu, Zunhai Zhou, Qiu Zhang, Xuefeng Li, Zhongyan Shan, Yaoming Xue, Hong Mao, Lixin Shi, Shandong Ye, Xiaomei Zhang, Jiao Sun, Ping Li, Tao Yang, Feng Li, Jingna Lin, Zhinong Zhang, Ying Zhao, Ruonan Li, Xiaohui Guo, Qi Yao, Weiping Lu, Shen Qu, Hongmei Li, Liling Tan, Wenbo Wang, Yongli Yao, Daoxiong Chen, Yulan Li, Jialin Gao, Wen Hu, Xiaoqiang Fei, Tianfeng Wu, Song Dong, Wenlong Jin, Chenzhong Li, Dong Zhao, Bo Feng, Yu Zhao, Yi Zhang, Xiaoying Li, Li Chen. Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial.
Nature medicine.
2022 05; 28(5):974-981. doi:
10.1038/s41591-022-01803-5. [PMID: 35551292] - Jia Miao, Ping Fu, Shuang Ren, Chao Hu, Ying Wang, Chengfeng Jiao, Ping Li, Yu Zhao, Cui Tang, Yuli Qian, Rong Yang, Yanli Dong, Jing Rong, Yaohui Wang, Xiaowei Jin, Yu Sun, Li Chen. Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual-acting glucokinase activator.
Clinical and translational science.
2022 02; 15(2):548-557. doi:
10.1111/cts.13174. [PMID: 34706161] - Rong Yang, Shuang Ren, Xiaowei Jin, Yu Sun, Yanli Dong, Jinwei Zhang, Wenzhong Liang, Li Chen. Determination of unbound fraction of dorzagliatin in human plasma by equilibrium dialysis and LC-MS/MS and its application to a clinical pharmacokinetic study.
Journal of pharmaceutical and biomedical analysis.
2021 Feb; 195(?):113854. doi:
10.1016/j.jpba.2020.113854. [PMID: 33388639] - Ling Song, Yi Zhang, Ji Jiang, Shuang Ren, Li Chen, Dongyang Liu, Xijing Chen, Pei Hu. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
Clinical pharmacokinetics.
2018 10; 57(10):1307-1323. doi:
10.1007/s40262-018-0631-z. [PMID: 29626326] - Xiao-Xue Zhu, Da-Long Zhu, Xiao-Ying Li, Ya-Lin Li, Xiao-Wei Jin, Tian-Xin Hu, Yu Zhao, Yong-Guo Li, Gui-Yu Zhao, Shuang Ren, Yi Zhang, Yan-Hua Ding, Li Chen. Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection.
Diabetes, obesity & metabolism.
2018 09; 20(9):2113-2120. doi:
10.1111/dom.13338. [PMID: 29707866]